Price check
No vendor listings yet
We do not track a vendor for Sabroxy (Oroxylin A) yet.
Nootropic profile
Sabroxy (Oroxylin A)
Flavonoid, NaturalSabroxy is a standardized extract of Oroxylum indicum bark containing 10% oroxylin A, a flavonoid that blocked dopamine uptake in lab tests on cells. Its one published trial gave 500 mg twice a day or placebo to 82 adults aged 60 to 85 with memory complaints (42 took the extract): after 12 weeks, episodic memory and some computer memory tasks improved more than on placebo, while the overall MoCA score and the other tests did not differ. Sabinsa Corporation funded the trial, supplied the extract, approved the study design and helped write the article, and one author was the founder and chairman of the Sami-Sabinsa Group. The trial dose, 1,000 mg a day, is far above the 50 to 150 mg listed on this profile.
View full peptide compound profile- Onset
- 30 min
- Duration
- 6 h
- Half-life
- 4 h
- Cycling
- Not required
- Legal status
- Listed as legal
01Mechanism
How it works
In lab tests on cells, oroxylin A blocked dopamine uptake much as methylphenidate, a dopamine transporter (DAT) blocker, does, and it did not block norepinephrine uptake. In spontaneously hypertensive rats, a strain used as a model of ADHD, it eased inattention and impulsivity, and the authors proposed stronger dopamine signaling as the cause. At GABA-A receptors it acts as an antagonist at the benzodiazepine site, not a positive modulator: it displaced a benzodiazepine from rat brain membranes, had no benzodiazepine-like effects of its own in rodent tests, and blocked the anti-anxiety and muscle-relaxing effects of diazepam (not its sedative or anti-seizure effects). These findings come from cells and rodents.
Pathways
Effects listed
- Role in a stack
- Primary
- Related brain health page
- Dopamine Optimization Protocol
02Evidence
Studies on file
- 2013
Oroxylin A improves attention deficit hyperactivity disorder-like behaviors in the spontaneously hypertensive rat and inhibits reuptake of dopamine in vitro
Archives of Pharmacal Research
In spontaneously hypertensive rats, a model of ADHD, oroxylin A eased inattention and impulsivity, and the dopamine blocker haloperidol weakened its effect on impulsivity. In cells, oroxylin A blocked dopamine uptake, as methylphenidate does, but not norepinephrine uptake. This tested oroxylin A alone, not the Sabroxy extract.
PubMed 23371806
Study notes from our compound data. A PubMed number opens that paper. A title search means the stored PubMed number did not match the study, so the note has not been checked against the paper.
03Dosing
Dosing guide
- Beginner50 mg
- Standard100 mg
- Advanced150 mg
- Frequency
- once daily
Fat-soluble: take with a fat source (e.g., fish oil, MCT oil) for better absorption.
Start low and increase gradually. Individual responses vary.
04Cycling
Cycling
No cycling required
No study has tested whether Sabroxy needs cycling. The one published trial gave it every day for 12 weeks.
Tolerance risk: Low
05Safety
Side effects and safety
Safety is a 1 to 5 score stored with each compound, 5 the safest. How each score was set is not recorded, so read it as an editorial summary, not a clinical grade.
Side effects listed
- Digestive complaints such as loose stools, nausea and bloating (1 trial, at 1,000 mg a day)
- Headaches (1 trial; one person on the extract stopped taking it)
Contraindications
- MAO inhibitors
Drug interactions
06Pairing
Pairings in our data
Avoid pairing with
07Buying
Where to buy
Estimated cost: no estimate in our data
08Questions
Frequently asked questions
Further reading
Want help from a coach?
The coaches in our directory are independent and take bookings.
Get nootropic research by email
Guides on compounds like Sabroxy (Oroxylin A): dosing, interactions and stacking. No set schedule. Unsubscribe anytime.
Was this page helpful?